<p><strong><span class="xn-location">SOUTH SAN FRANCISCO</span></strong> &#8212; Freenome, a privately held biotech company, announced that Swiss healthcare giant Roche has made an investment of <span class="xn-money">$290 million</span>, bringing Freenome&#8217;s total funding to more than <span class="xn-money">$1.1 billion</span> since the company was founded in 2014. This funding follows Freenome&#8217;s recent <u>Series D</u> financing of <span class="xn-money">$300 million</span> in December.</p>
<p>Detecting cancer early, when it&#8217;s most treatable, improves survival rates. Each year, approximately 53,000 Americans die from colorectal cancer (CRC). If diagnosed early when localized, the survival rate for CRC is over 90%, compared to only 14% once the cancer has spread.</p>
<p>Freenome has developed a machine learning-enabled multiomics blood test for CRC screening, which is being validated in PREEMPT CRC, its large, prospective registrational study that is in the final stages of enrollment.</p>
<p>The company is also extending its multiomics platform with biomarkers for other cancer types currently embedded to develop tests in new indications, and recently presented promising <u>data</u> in the detection of pancreatic cancer. Next month, the company will expand and launch additional multicancer clinical studies focused on more tailored baskets of screening tests, based on an individual&#8217;s risk.</p>
<p>&#8220;With Roche&#8217;s investment and expertise, we&#8217;ll be able to further accelerate and augment the development of our platform to test for additional cancers, and expand our real-world data programs,&#8221; said <span class="xn-person">Mike Nolan</span>, chief executive officer of Freenome. &#8220;From the beginning, our focus has been on ensuring our tests will be available for everyone and Roche&#8217;s support brings us closer to making that a reality.&#8221;</p>
<p>&#8220;We are happy to support Freenome&#8217;s innovative approach to early cancer detection,&#8221; said Thomas Schinecker, CEO of Roche Diagnostics. &#8220;We believe blood-based multimodal screening and data-driven medical insights will help deliver personalized healthcare. This investment will be an important step to advance early cancer screening, and we look forward to joining Freenome in this journey.&#8221;</p>

FREMONT -- EnerVenue Holdings, a company commercializing energy storage solutions designed to behave like durable…
Nasdaq announced that memory provider Sandisk Corporation will be added to the prestigious Nasdaq-100 Index…
SAN JOSE -- Bloom Energy has announced an expanded partnership with Oracle to support the rapid…
SAN FRANCISCO -- Luminai, an AI-native enterprise automation platform built for healthcare operations, has closed a $38…
Meta has formed a partnership with British semiconductor firm Arm to develop a new class…
SANTA CLARA -- SiFive, a chip design firm, has raised $400 million in an oversubscribed…